Castle Biosciences
CSTL
57 hedge funds and large institutions have $88.1M invested in Castle Biosciences in 2019 Q3 according to their latest regulatory filings, with 57 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
28.52% more ownership
Funds ownership: 0% → 28.52% (+29%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$16.5M |
| 2 |
Goldman Sachs
New York
|
+$6.69M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$6.22M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$6.11M |
| 5 |
BlackRock
New York
|
+$4.59M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FCM
51
Flinton Capital Management
Philadelphia,
Pennsylvania
| $22K | +$27.3K | +1,232 | New |
|
|
SO
52
STRS Ohio
Columbus,
Ohio
| $18K | +$22.2K | +1,000 | New |
|
53
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $16K | +$22.7K | +1,023 | New |
|
54
Legal & General Group
London,
United Kingdom
| $10K | +$12.8K | +576 | New |
|
|
AIP
55
Ameritas Investment Partners
Lincoln,
Nebraska
| $6K | +$6.87K | +310 | New |
|
|
CCA
56
Catalyst Capital Advisors
Huntington,
New York
| $5K | +$6.65K | +300 | New |
|
57
Citigroup
New York
| $3K | +$3.61K | +163 | New |
|
CSTL Hedge Fund Activity: Q3 2019 in Review
57 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q3 2019, worth a combined $88.1M.
Buyers outnumbered sellers: 57 funds opened new CSTL positions and 0 closed out — a net gain of 57 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $16.5M.
- 57 institutional investors held Castle Biosciences (CSTL) as of Q3 2019, up from 0 in Q2 2019.
- Funds reported $88.1M of Castle Biosciences stock for Q3 2019.
- 57 funds opened new Castle Biosciences positions in Q3 2019 and 0 closed out, a net change of +57 holders.
- The largest Castle Biosciences buyer in Q3 2019 was RTW Investments, an estimated $16.5M added.
Based on aggregated 13F filings for Q3 2019.